Home » Topics » Regulatory » EMA

EMA
RSS

Abbott withdraws European MAA for Ozespa

Jan. 19, 2011

No Comments

ChemGenex notifies EMA of withdrawal of MAA for Tekinex for Ph+ CML

Jan. 17, 2011

No Comments

New indication for Lucentis in E.U. for vision loss in diabetic macular edema

Jan. 11, 2011

No Comments

EMA and FDA grant expedited review for boceprevir

Jan. 11, 2011

No Comments

Invega approved in E.U. for schizoaffective disorder

Jan. 7, 2011

No Comments

EMA to review Allos' MAA for Folotyn in relapsed or refractory PTCL

Dec. 28, 2010

No Comments

Novartis receives E.U. approval for Tasigna in newly diagnosed Ph+ CML

Dec. 27, 2010

No Comments

CHMP recommends marketing authorization for Janssen-Cilag's Xeplion

Dec. 23, 2010

No Comments

CHMP recommends a variation to marketing terms for Simponi

Dec. 23, 2010

No Comments

CHMP recommends approval of Teysuno for treatment of advanced gastric cancer

Dec. 23, 2010

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

EMA
RSS

Abbott withdraws European MAA for Ozespa

ChemGenex notifies EMA of withdrawal of MAA for Tekinex for Ph+ CML

New indication for Lucentis in E.U. for vision loss in diabetic macular edema

EMA and FDA grant expedited review for boceprevir

Invega approved in E.U. for schizoaffective disorder

EMA to review Allos' MAA for Folotyn in relapsed or refractory PTCL

Novartis receives E.U. approval for Tasigna in newly diagnosed Ph+ CML

CHMP recommends marketing authorization for Janssen-Cilag's Xeplion

CHMP recommends a variation to marketing terms for Simponi

CHMP recommends approval of Teysuno for treatment of advanced gastric cancer

Today's news in brief

Today's news in brief

In muscular dystrophies, gene therapies race the clock

Bridgebio, with FDA approval, faces Pfizer in ATTR

Radiopharma Telix acquires FAP-targeting agents for bladder cancer

EMA RSS

EMA
RSS